Ionova Entered into a Clinical Trial Collaboration with MSD to Evaluate INV-1120 + Keytruda (pembrolizumab) for Advanced Solid Tumors
Shots:
- The companies collaborated to evaluate the clinical benefits of Ionova's INV-1120 (EP4 antagonist) + MSD's Keytruda in the P-Ib study for the treatment of selected advanced solid tumors. Ionova will be responsible to conduct a P-Ib study in the US
- In the preclinical solid tumor models study, INV-1120 showed mono therapeutic anti-cancer efficacy along with strong additive anti-cancer benefits in combination with Keytruda & increase anti-tumor immune responses
- INV-1120 is a highly potent, highly selective & orally available EP4 antagonist & is designed to modulate the tumor microenvironment. The therapy has increased T cell infiltration and regulates macrophage functions in tumors
Ref: PRNewswire | Image: Ionova
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
